Key result
Low-dose pioglitazone (15 mg) significantly decreased fasting blood glucose (155.2 to 131.1 mg/dl, p<0.01) and HbA1C (7.13 to 6.69, p<0.001) without affecting natriuretic peptides.
Why the study?
Does low-dose pioglitazone improve glucose control and lipid profiles without adversely affecting the RAA system and natriuretic peptides in diabetic patients with coronary artery disease and preserved LVEF?
Population
22 diabetic patients with coronary artery disease and left ventricular ejection fraction (LVEF) >40%
Design
Cohort
Follow-up
12 weeks
Authors
Loading...
May support glycemic control in diabetic CAD with preserved LVEF without NP changes; hypothesis-generating and requires RCTs before practice consideration.
Does low-dose pioglitazone improve glucose control and lipid profiles without adversely affecting the RAA system and natriuretic peptides in diabetic patients with coronary artery disease and preserved LVEF?
Absolute Event Rate: 131.1% vs 155.2%
p-value: p=<0.01
Low-dose pioglitazone improves glycemic control and triglycerides without activating the RAA system or increasing natriuretic peptides in diabetic patients with CAD and preserved LVEF.
Kurisu et al. (2012) studied diabetic patients with coronary artery disease (n=22). pioglitazone vs. baseline was evaluated on fasting blood glucose (p=<0.01). Low-dose pioglitazone (15 mg) significantly decreased fasting blood glucose (155.2 to 131.1 mg/dl, p<0.01) and HbA1C (7.13 to 6.69, p<0.001) without affecting natriuretic peptides.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: